Clinical trial • Not applicable • Neurology

ROPIVACAINE for Anesthesia | Intensive care

Not applicable trial of ROPIVACAINE for Anesthesia | Intensive care.

Overview

Trial Therapeutic Area
Neurology
Trial Disease
Anesthesia | Intensive care
Trial Stage
Not applicable
Drug Modality
Small molecule

Key dates

Initial CTIS Submission Date
02-07-2024
First CTIS Authorization Date
30-07-2024

Trial design

Randomised, two parallel arms: groupe al (anesthésie locale) - infiltration locale par 10 ml de lidocaïne 20 mg/ml non adrénalinée; groupe s (bloc serratus) - injection sous échoguidage de 30 ml ropivacaine 4,75 mg/ml.-controlled Not applicable trial across 1 site in France.

Randomised
Yes
Comparator
Two parallel arms: Groupe AL (Anesthésie locale) - infiltration locale par 10 mL de Lidocaïne 20 mg/mL non adrénalinée; Groupe S (Bloc Serratus) - Injection sous échoguidage de 30 mL Ropivacaine 4,75 mg/mL.
Target Sample Size
70
Trial Duration For Participant
1

Stratification factors

  • Baseline pain (EN) category (1-3, 4-6, 7-10)
  • Care unit/service

Eligibility

Recruits 70 Vulnerable population not selected. Patients under guardianship or curatorship or deprived of liberty are excluded. Inclusion requires 'Free and informed consent signed.'.

Pregnancy Exclusion
Pregnant, parturient or breastfeeding woman.
Vulnerable Population
Vulnerable population not selected. Patients under guardianship or curatorship or deprived of liberty are excluded. Inclusion requires 'Free and informed consent signed.'

Inclusion criteria

  • {"criterion_text":"- Patient aged 18 or over, not intubated, spontaneously ventilating."}
  • {"criterion_text":"- Free and informed consent signed."}
  • {"criterion_text":"- Affiliate to a social security scheme."}
  • {"criterion_text":"- Hospitalized in multipurpose intensive care unit including surgical resuscitation, cardiothoracic and respiratory resuscitation or continuing cardiothoracic and respiratory care services."}
  • {"criterion_text":"- Requiring gas or fluid pleural drainage."}

Exclusion criteria

  • {"criterion_text":"- Patient didn't agree to participate in the trial."}
  • {"criterion_text":"- Patient under guardianship or curatorship or deprived of liberty."}
  • {"criterion_text":"- Pregnant, parturient or breastfeeding woman."}
  • {"criterion_text":"- Allergy and contraindication to Lidocaine or Ropivacaine."}
  • {"criterion_text":"- Coagulation disorders."}

Endpoints

Primary endpoints

  • {"endpoint_text":"- Intensity of acute pain during pleural drainage (H0) by numerical scale (EN).","definition_or_measurement_approach":"Measured at H0 using a numerical scale (EN) during pleural drainage."}

Secondary endpoints

  • {"endpoint_text":"- Intensity of acute pain by EN at rest and during exercise (forced inspiration) at the end of pleural drainage (H0).","definition_or_measurement_approach":"Measured at H0 using numerical scale (EN) at rest and during forced inspiration."}
  • {"endpoint_text":"- Intensity of acute pain from EN at rest and during exercise (cough and forced inspiration) after drainage over the first 24 hours (H0, H1, H6, H24).","definition_or_measurement_approach":"Measured using EN at timepoints H0, H1, H6, H24 at rest and during cough and forced inspiration."}
  • {"endpoint_text":"- Clinical tolerance at the end of drainage (H0): MAP HR, FR, SpO2.","definition_or_measurement_approach":"Clinical parameters measured at H0: mean arterial pressure (MAP), heart rate (HR), respiratory rate (FR), SpO2."}
  • {"endpoint_text":"- Lung capacity in milliliters measured by the Voldyne (maximum inspired volume) H1, H6, H24.","definition_or_measurement_approach":"Maximum inspired volume measured by Voldyne at H1, H6, H24."}
  • {"endpoint_text":"- Respiratory complications: - atelectasis = auscultation + radiography or ultrasound - nosocomial pneumonia = 3 clinicoradiological criteria compatible with radiological infiltrate + hyperthermia (>38 or <36°C) or leukocytes (>12000 or <4000 GB/mm3) + purulent aspirations or suggestive auscultation or hypoxemia.","definition_or_measurement_approach":"Respiratory complications defined as: atelectasis by auscultation plus radiography/ultrasound; nosocomial pneumonia defined by 3 clinicoradiological criteria plus hyperthermia or leukocyte criteria and purulent aspirations or evocative auscultation or hypoxemia."}
  • {"endpoint_text":"- Use of tracheal intubation.","definition_or_measurement_approach":"Occurrence of tracheal intubation during follow-up."}
  • {"endpoint_text":"- Early rehabilitation: time to first getting up, physiotherapy.","definition_or_measurement_approach":"Time to first ambulation and initiation of physiotherapy."}
  • {"endpoint_text":"- Duration of drainage.","definition_or_measurement_approach":"Measured duration of pleural drainage."}
  • {"endpoint_text":"- Duration of stay in intensive care.","definition_or_measurement_approach":"Length of ICU stay."}
  • {"endpoint_text":"- Duration of installation of anesthesia.","definition_or_measurement_approach":"Time required to install anesthesia."}

Recruitment

Planned Sample Size
70
Recruitment Window Months
83
Consent Approach
Informed consent: 'Free and informed consent signed.' Consent must be provided and signed by the participant. Patients under guardianship or curatorship or deprived of liberty are excluded. A subject information and informed consent form for adults (L1) is listed.

Geography

Total Number Of Sites
1
Total Number Of Participants
70

France

Earliest CTIS Part Ii Submission Date
10-07-2024
Latest Decision Or Authorization Date
30-07-2024
Processing Time Days
20
Number Of Sites
1
Number Of Participants
70

Sites

Site Name
Centre Hospitalier Universitaire Amiens Picardie
Department Name
Pôle d’Anesthésie-Réanimation
Principal Investigator Name
Stéphanie MALAQUIN
Principal Investigator Email
malaquin.stephanie@chu-amiens.fr
Contact Person Name
Stéphanie MALAQUIN
Number Of Participants
70

Sponsor

Primary sponsor

Full Name
Centre Hospitalier Universitaire Amiens Picardie
Organisation Type
Hospital/Clinic/Other health care facility
Country Of Registered Address
France

Investigational products

Investigational Product Name
ROPIVACAINE
Active Substance
ROPIVACAINE
Modality
Small molecule
Routes Of Administration
INFILTRATION
Route
INFILTRATION
Starting Dose
Injection sous échoguidage de 30 mL Ropivacaine 4,75 mg/mL
Maximum Dose
225 mg
Investigational Product Name
LIDOCAINE HYDROCHLORIDE
Active Substance
LIDOCAINE HYDROCHLORIDE
Modality
Small molecule
Routes Of Administration
INFILTRATION
Route
INFILTRATION
Starting Dose
Infiltration locale par 10 mL de Lidocaïne 20 mg/mL non adrénalinée
Maximum Dose
400 mg
Investigational Product Name
DEXAMETHASONE SODIUM PHOSPHATE
Active Substance
DEXAMETHASONE SODIUM PHOSPHATE
Modality
Small molecule
Routes Of Administration
INTRAVENOUS
Route
INTRAVENOUS
Starting Dose
8 mg
Maximum Dose
8 mg

Related trials

Other published trials that may interest you.